Search research articles
Contact Us
Filters
Showing results (91-100 of 111) with videos related to
Page
of 12
Sort By:
International Journal of Radiation Oncology, Biology, Physics
|
December 14, 2020
Clinical Outcomes of a Randomized Trial of Adaptive Plan-of-the-Day Treatment in Patients Receiving Ultra-hypofractionated Weekly Radiation Therapy for Bladder Cancer
Robert Huddart, Shaista Hafeez, Rebecca Lewis, et al.
Cancer Medicine
|
March 24, 2022
Pharmacogenomics of cisplatin-induced neurotoxicities: Hearing loss, tinnitus, and peripheral sensory neuropathy
Xindi Zhang, Matthew R Trendowski, Emma Wilkinson, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 13, 2017
COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss
Simon J Crabb, Karen Martin, Julia Abab, et al.
Eclinicalmedicine
|
April 13, 2026
Impact of cisplatin dose, renal function, and other factors on audiometrically-assessed ototoxicity in more than 1400 adult-onset cancer survivors from The Platinum Study: a multicentre cohort study
Victoria A Sanchez, Paul C Dinh, Patrick O Monahan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 15, 2016
Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer
Cora Sternberg, Andrew Armstrong, Roberto Pili, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
May 16, 2019
Adverse Health Outcomes in Relationship to Hypogonadism After Chemotherapy: A Multicenter Study of Testicular Cancer Survivors
Mohammad Abu Zaid, Paul C Dinh, Patrick O Monahan, et al.
Familial Cancer
|
July 18, 2009
Younger age-at-diagnosis for familial malignant testicular germ cell tumor
Phuong L Mai, Bingshu E Chen, Kathy Tucker, et al.
European Urology
|
October 8, 2024
Dose-escalated Adaptive Radiotherapy for Bladder Cancer: Results of the Phase 2 RAIDER Randomised Controlled Trial
Robert Huddart, Shaista Hafeez, Clare Griffin, et al.
Nature Communications
|
May 6, 2020
Genomic landscape of platinum resistant and sensitive testicular cancers
Chey Loveday, Kevin Litchfield, Paula Z Proszek, et al.
British Journal of Cancer
|
September 30, 2023
Outcomes of relapsed clinical stage I versus de novo metastatic testicular cancer patients: an analysis of the IGCCCG Update database
Jakob Lauritsen, Nicolas Sauvé, Alexey Tryakin, et al.
Page
of 12
Search research articles
Search
Showing results (91-100 of 111) with videos related to
Sort By:
Page
of 12
International Journal of Radiation Oncology, Biology, Physics
|
December 14, 2020
Clinical Outcomes of a Randomized Trial of Adaptive Plan-of-the-Day Treatment in Patients Receiving Ultra-hypofractionated Weekly Radiation Therapy for Bladder Cancer
Robert Huddart, Shaista Hafeez, Rebecca Lewis, et al.
Cancer Medicine
|
March 24, 2022
Pharmacogenomics of cisplatin-induced neurotoxicities: Hearing loss, tinnitus, and peripheral sensory neuropathy
Xindi Zhang, Matthew R Trendowski, Emma Wilkinson, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 13, 2017
COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss
Simon J Crabb, Karen Martin, Julia Abab, et al.
Eclinicalmedicine
|
April 13, 2026
Impact of cisplatin dose, renal function, and other factors on audiometrically-assessed ototoxicity in more than 1400 adult-onset cancer survivors from The Platinum Study: a multicentre cohort study
Victoria A Sanchez, Paul C Dinh, Patrick O Monahan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 15, 2016
Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer
Cora Sternberg, Andrew Armstrong, Roberto Pili, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
May 16, 2019
Adverse Health Outcomes in Relationship to Hypogonadism After Chemotherapy: A Multicenter Study of Testicular Cancer Survivors
Mohammad Abu Zaid, Paul C Dinh, Patrick O Monahan, et al.
Familial Cancer
|
July 18, 2009
Younger age-at-diagnosis for familial malignant testicular germ cell tumor
Phuong L Mai, Bingshu E Chen, Kathy Tucker, et al.
European Urology
|
October 8, 2024
Dose-escalated Adaptive Radiotherapy for Bladder Cancer: Results of the Phase 2 RAIDER Randomised Controlled Trial
Robert Huddart, Shaista Hafeez, Clare Griffin, et al.
Nature Communications
|
May 6, 2020
Genomic landscape of platinum resistant and sensitive testicular cancers
Chey Loveday, Kevin Litchfield, Paula Z Proszek, et al.
British Journal of Cancer
|
September 30, 2023
Outcomes of relapsed clinical stage I versus de novo metastatic testicular cancer patients: an analysis of the IGCCCG Update database
Jakob Lauritsen, Nicolas Sauvé, Alexey Tryakin, et al.
Page
of 12